3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 3
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
4
Lymphoid
2
Sarcoma
1
Myeloid
1
Conditions
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
Imatinib Mesylate
28
nilotinib
21
Cytarabine
21
Methotrexate
16
Hydroxyurea
15
Cyclophosphamide
15
Busulfan
15
Peripheral Blood Stem Cell Transplantation
13
ruxolitinib
11
Etoposide
11
Whole-Body Irradiation
10
fludarabine phosphate
9
fludarabine
9
Tacrolimus
9
Mycophenolic Acid
9
Daunorubicin
9
Idarubicin
8
Radiotherapy
7
Mitoxantrone
7
Interferon-alpha
7
Cyclosporine
6
peginterferon alfa-2a
5
bosutinib
5
asciminib
5
Melphalan
5
Azacitidine
5
merphos
4
luspatercept
4
Thioguanine
4
Filgrastim
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
olverembatinib
×
Myeloid
×
Clear all
NCT06423911
2025-06-03
POLARIS-2
Ascentage Pharma Group Inc.
Phase 3
Recruiting
285 enrolled